CP 316311 is a selective β3-adrenergic receptor (β3-AR) agonist primarily investigated for its therapeutic potential in treating obesity and type 2 diabetes. It activates β3-ARs in adipose tissue and brown fat, promoting lipolysis, thermogenesis, and increased energy expenditure, which can lead to reduced body weight and improved insulin sensitivity. This compound is used in pharmacological research to study β3-AR signaling pathways involved in metabolism and energy homeostasis. Additionally, it serves as a tool in preclinical studies for developing novel anti-obesity and antidiabetic drugs, including safety and efficacy testing before clinical trials.